Skip to content
value.today

Repros Therapeutics Inc.

Formerly Zonagen, Inc.

Total raised
$30 M
2 rounds on record
Latest round
$24 M
Sep 2012
First round on record
Oct 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Repros Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2012$24 MNo. 2$10 to $50 million

Repros Therapeutics Inc.: Raise no. 2, Sep 2012

Investors in this round

15 investors had bought by the notice of Sep 19, 2012: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $24 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$300,000
Finders' fees
none
Paid to its own people
$985,300 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph S. Podolski · Executive Officer, Director
  • Katherine S. Anderson · Executive Officer
  • Daniel S. Cain · Director
  • Jaye S. Thompson, Ph.D. · Director
  • Jean S. Fourcroy · Director
  • Michael S. Wyllie, Ph.D. · Director
  • Nola S. Masterson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Trout Capital LLC (CRD 131489) · broker-dealer Trout Capital LLC (CRD 131489) · New York City, New YorkSold in all US states

Signed by Katherine Anderson, Chief Financial Officer. Newest notice filed Sep 19, 2012. Read the notice at the SEC.

equitySEC
Oct 2009$6 MNo. 1$2 to $10 million

Repros Therapeutics Inc.: Raise no. 1, Oct 2009

Investors in this round

9 investors had bought by the notice of Nov 12, 2009: 7 accredited, 2 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph S. Podolski · Executive Officer, Director
  • Katherine S. Anderson · Executive Officer
  • Daniel F. Cain · Director
  • Jean L. Fourcroy · Director
  • Mark S. Lappe · Director
  • Nola L. Masterson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph S. Podolski, Chief Executive Officer. Newest notice filed Nov 12, 2009. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Repros Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2012).

    SEC Form D · Sep 2012

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2012

Products and services#

No products or services on record: its website does not allow automated readers.

Investors#

No investor of Repros Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Repros Therapeutics Inc.
NameRoleNamed in
Joseph S. PodolskiExecutive officerSep 2012
Katherine S. AndersonExecutive officerSep 2012
Daniel S. CainDirectorSep 2012
Jaye S. Thompson, Ph.D.DirectorSep 2012
Jean S. FourcroyDirectorSep 2012
Joseph S. PodolskiDirectorSep 2012
Michael S. Wyllie, Ph.D.DirectorSep 2012
Nola S. MastersonDirectorSep 2012
Daniel F. CainDirectorNov 2009
Jean L. FourcroyDirectorNov 2009
Mark S. LappeDirectorNov 2009
Nola L. MastersonDirectorNov 2009

About

American pharmaceutical company.